NCT03379259 - Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 27, 2017

Primary Completion Date

September 8, 2020

Study Completion Date

September 8, 2020

Conditions

Advanced Solid Tumors

Interventions

DRUG

BGB-A333

Anti-PD-L1 antibody

DRUG

BGB-A317

Anti-PD-1 antibodies

Trial Locations (8)

Auckland City Hospital, Auckland

Peter Maccallum Cancer Centre, Melbourne

Nucleus Network, Melbourne

Monash Health, Clayton

Linear Clinical Research, Nedlands

Start Madrid Fundacion Jimenez Diaz, Madrid

Centro Integral Oncologico Clara Campal, Madrid

Institut Catala Doncologia, Barcelona